Juan Lantero Rodriguez

List of Publications by Year
in descending order

33	3,059	279798 23	414414 32
papers	citations	h-index	g-index

33	33	33	2025
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	7.6	20
2	Plasma pâ€tau231, pâ€tau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	5.3	42
3	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	6.1	65
4	CSF biomarkers and plasma pâ€tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.8	22
5	Plasma biomarkers for Alzheimerâ€™s Disease in relation to neuropathology and cognitive change. Acta Neuropathologica, 2022, 143, 487-503.	7.7	89
6	Biomarker modeling of Alzheimerâ€™s disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	11.6	73
7	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews Neurology, 2022, 18, 400-418.	10.1	99
8	Population-based blood screening for pre-clinical Alzheimerâ€™s disease: a British birth cohort at age 70. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A91.2-A91.	1.9	0
9	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimerâ€™s disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
10	Headâ€toâ€head comparison of clinical performance of CSF phosphoâ€tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's and Dementia, 2021, 17, 755-767.	0.8	81
11	Time course of phosphorylated-tau181 in blood across the Alzheimerâ€™s disease spectrum. Brain, 2021, 144, 325-339.	7.6	124
12	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimerâ€™s Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	7.9	186
13	Association between polygenic risk score of Alzheimerâ€™s disease and plasma phosphorylated tau in individuals from the Alzheimerâ€™s Disease Neuroimaging Initiative. Alzheimer's Research and Therapy, 2021, 13, 17.	6.2	35
14	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	5.2	17
15	Plasma p-tau231: a new biomarker for incipient Alzheimerâ€™s disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
16	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 69.	6.2	34
17	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	3.3	15
18	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146

#	Article	IF	Citations
19	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54
20	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.1	50
21	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimerâ€™s disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	12.8	33
22	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
23	OUP accepted manuscript. Brain, 2021, 144, 434-449.	7.6	54
24	Pâ€tau235: a novel biomarker for staging preclinical Alzheimerâ€™s disease. EMBO Molecular Medicine, 2021, 13, e15098.	6.9	30
25	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Communications Biology, 2021, 4, 1265.	4.4	4
26	Distinctive effect of biological sex in ADâ€related CSF and plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.8	2
27	Plasma p-tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8Âyears prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica, 2020, 140, 267-278.	7.7	209
28	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 77, 1129-1141.	2.6	55
29	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimerâ€™s continuum when only subtle changes in AÎ² pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
30	Plasma pâ€tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8 years prior to postâ€mortem and improves the clinical characterisation of cognitive decline. Alzheimer's and Dementia, 2020, 16, e047539.	0.8	2
31	Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	1.9	93
32	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	10.2	668
33	AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia, 2017, 60, 729-739.	6.3	20